Abstract
Cancer has a complex biology and has been characterized by several hallmarks during its multistep progression such as sustaining proliferation, evading growth suppressors, resisting cell death, stimulating angiogenesis, activation of invasion and metastasis, etc. There is an increased understanding of complex biology of cancer in the past few decades; still this disease remains the primary cause of death in developed and developing countries all over the globe.
The efforts to reduce global cancer burden are mainly focused on developing innovative diagnostic and therapeutic tools. In this process of translation, animal models play a crucial role in translating diagnostic and therapeutic innovations to human clinical trials. Animal models are historically used in medical research initially for understanding of basic anatomy and physiology till developing new treatments for various diseases including cancer. The early twentieth century has seen a dramatic increase in the use of animal models, and since then the refinements of these models are happening untiringly. The refinements or improvements in model systems are required with increase in our understanding of human and animal biology as well as disease processes. This chapter deals with anticancer drug developments before and after arrival of immunocompromised animals in cancer research and various thought processes going on during the last century with respect to anticancer drug research. The authors have touched upon various advantages and disadvantages of model systems used in drug development. This chapter also includes current approaches towards cancer model systems along with upcoming models showing potential to expedite drug development process with reduction in attrition rate.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abate-Shen C, Shen MM (2002) Mouse models of prostate carcinogenesis. Trends Genet 18(5):S1–S5
American Cancer Society Cancer facts and figures 2014. Accessed April 2 Afhwcoagcrdwa-p
Aytes A, Molleví DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A et al (2012) Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol Carcinog 51(9):746–753
Baioni E, Scanziani E, Vincenti MC, Leschiera M, Bozzetta E, Pezzolato M et al (2017) Estimating canine cancer incidence: findings from a population-based tumour registry in northwestern Italy. BMC Vet Res 13(1):203
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C et al (2011) A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508–523
Boone JD, Dobbin ZC, Straughn JM Jr, Buchsbaum DJ (2015) Ovarian and cervical cancer patient derived xenografts: the past, present, and future. Gynecol Oncol 138(2):486–491
Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, Fodstad Ø et al (1992) Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52(21):5940–5947
Brehm MA, Cuthbert A, Yang C, Miller DM, DiIorio P, Laning J et al (2010) Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rγnull mutation. Clin Immunol 135(1):84–98
Brehm MA, Shultz LD, Luban J, Greiner DL (2013) Overcoming current limitations in humanized mouse research. J Infect Dis 208(Suppl 2):S125–SS30
Carr BI (1985) Chemical carcinogens and inhibitors of carcinogenesis in the human diet. Cancer 55(S1):218–224
Choi YY, Lee JE, Kim H, Sim MH, Kim K-K, Lee G et al (2016) Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 6:22172
Connors T, Roe F (1964) Antitumour agents. Evaluation of drug activities. Pharmacometrics 2:827–874
Cook JW, Hieger I, Kennaway EL, Mayneord WV (1932) The production of cancer by pure hydrocarbons.—Part I. Proce R Soc Lond Ser B 111(773):455–484
Decker S, Sausville E (2011) Perspectives on the history and evolution of tumor models. Tumor models in cancer research. Springer, New York, pp 3–20
DeRose YS, Wang G, Lin Y-C, Bernard PS, Buys SS, Ebbert MT et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514
DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653
Doetschman T, Azhar M (2012) Cardiac-specific inducible and conditional gene targeting in mice. Circ Res 110(11):1498–1512
Ericsson AC, Crim MJ, Franklin CL (2013) A brief history of animal modeling. Mo Med 110(3):201
Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A et al (2008) Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14(20):6456–6468
Fiebig H (1988) Comparison of tumor response in nude mice and in patients. Human tumour xenografts in anticancer drug development. Springer, Berlin, pp 25–30
Filipiak WE, Saunders TL (2006) Advances in transgenic rat production. Transgenic Res 15(6):673–686
Findlay GM (1928) Ultra-violet light and skin cancer. Lancet 212:1070–1073
Forkert P-G (2010) Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 42(2):355–378
Garrido-Laguna I, Uson M, Rajeshkumar N, Tan AC, De Oliveira E, Karikari C et al (2011) Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17(17):5793–5800
Golovkina TV, Dudley JP, Ross SR (1998) B and T cells are required for mouse mammary tumor virus spread within the mammary gland. J Immunol 161(5):2375–2382
Hammer RE, Pursel VG, Rexroad CE, Wall RJ, Bolt DJ, Ebert KM et al (1985) Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315(6021):680
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Hansen K, Khanna C (2004) Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer 40(6):858–880
Hernandez B, Adissu H, Wei B-R, Michael H, Merlino G, Simpson R (2018) Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas. Int J Mol Sci 19(2):394
Higashijima S, Hotta Y, Okamoto H (2000) Visualization of cranial motor neurons in live transgenic zebrafish expressing green fluorescent protein under the control of the islet-1 promoter/enhancer. J Neurosci 20(1):206–218
Homburger F, Russfield A, Baker J, Tregier A, Kenney R, Crooker C et al (1962) Experimental chemotherapy in chemically induced mouse tumors and their transplants. Cancer Res 22(3):368–374
Hong SG, Kim MK, Jang G, Oh HJ, Park JE, Kang JT et al (2009) Generation of red fluorescent protein transgenic dogs. Genesis 47(5):314–322
Hursting SD, Nunez NP, Patel AC, Perkins SN, Lubet RA, Barrett JC (2005) The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res 576(1–2):80–92
Ikawa M, Kominami K, Yoshimura Y, Tanaka K, Nishimune Y, Okabe M (1995) A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP). FEBS Lett 375(1–2):125–128
Inoue K, Fujimoto S, Ogawa M (1983) Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice. Cancer Chemother Pharmacol 10(3):182–186
Jin K, Teng L, Shen Y, He K, Xu Z, Li G (2010) Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12(7):473–480
Jin K, He K, Han N, Li G, Wang H, Xu Z et al (2011) Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. Hepato-Gastroenterology 58(110–111):1814–1822
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18(19):5314–5328
Jung J (2014) Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res 30(1):1
Kennaway E (1955) The identification of a carcinogenic compound in coal-tar. Br Med J 2(4942):749
Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ et al (2013) A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 7(4):776–790
Khanna C, Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26(3):513–523
Khleif SN, Curt GA (2000) Animal models in developmental therapeutics. Holland-Frei Cancer Medicine, 5th edn. BC Decker, Hamilton
Kikutani H, Makino S (1992) The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51:285–322
Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M et al (2013) Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 19(4):855–864
Kinosita R (1936) Researches on the carcinogenesis of the various chemical substances. Gann 30:423–426
Kong D, Yamori T (2012) JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem 20(6):1947–1951
Krogh A (1929) The progress of physiology. Am J Physiol Legacy Content 90(2):243–251
Lawley PD (1994) Historical origins of current concepts of carcinogenesis. Advances in cancer research. Elsevier, Burlington, pp 17–111
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130
Liu M, Hicklin D (2011) Human tumor xenograft efficacy models. Tumor models in cancer research. Springer, New York, pp 99–124
Lunardi A, Nardella C, Clohessy JG, Pandolfi PP (2014) Of model pets and cancer models: an introduction to mouse models of cancer. Cold Spring Harbor Protocols 2014(1):pdb.top069757
Ma H, Li X, Yang Z, Okuno S, Kawaguchi T, Yagi S, Bouvet M, Hoffman RM (2011) High Antimetastatic efficacy of MEN4901/T-0128, a novel Camptothecin Carboxymethyldextran conjugate. J Surg Res 171(2):684–690
Magee P, Barnes J (1956) The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine. Br J Cancer 10(1):114
Magee P, Barnes J (1967) Carcinogenic nitroso compounds. Advances in cancer research. Elsevier, New York, pp 163–246
Marangoni E, Poupon M-F (2014) Patient-derived tumour xenografts as models for breast cancer drug development. Curr Opin Oncol 26(6):556–561
Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998
Miller JA (1991) The Need for Epidemiological Studies of the Medical Exposures of Japanese Patients to the Carcinogen Ethyl Carbamate (Urethane) from 1950 to 1975. Jpn J Cancer Res Gann 82(12):1323
Miller J, Miller E (1947) The metabolism and carcinogenicity of p-dimethylaminoazobenzene and related compounds in the rat. Cancer Res 7(1):39–41
Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L (2012) Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. Biomed Res Int 2012
Morton CL, Houghton PJ (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2(2):247
National Cancer Institute. Developmental therapeutics program. Data retrieval and testing decisions. (2015)
Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L et al (2010) Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 16(8):2352–2362
Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM et al (2004) PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 25(9):1747–1755
Orban PC, Chui D, Marth JD (1992) Tissue-and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci 89(15):6861–6865
Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2):147
Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M et al (2018) Comparative oncology approach to drug repurposing in osteosarcoma. PLoS One 13(3):e0194224
Pinello K, Niza-Ribeiro J, Fonseca L, de Matos A (2019) Incidence, characteristics and geographical distributions of canine and human non-Hodgkin’s lymphoma in the Porto region (North West Portugal). Vet J 245:70
Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. Anticancer drug development guide. Springer, New York, pp 101–125
Pott P (1776) CHIRURGICAL OBSERVATIONS relative to the CATARACT, the POLYPUS of the NOSE, the CANCER of the SCROTUM, the different Kinds of RUPTURES, and the MORTIFICATION of the TOES and FEET. The weekly entertainer and west of England miscellany. 5(129):622–625
Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51
Rehn L (1895) Blasengeschwure bei Fuchsinarbeitern. Arch Klin Chir 50:588–600
Reyes G, Villanueva A, García C, Sancho FJ, Piulats J, Lluís F et al (1996) Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 56(24):5713–5719
Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. The Company of Biologists Ltd
Ruddell A, Mezquita P, Brandvold KA, Farr A, Iritani BM (2003) B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol 163(6):2233–2245
Rygaard J, Poulsen CO (1969) Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathologica Microbiologica Scandinavica 77(4):758–760
Saito M, Iwawaki T, Taya C, Yonekawa H, Noda M, Inui Y et al (2001) Diphtheria toxin receptor–mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol 19(8):746
Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, Kamioka M et al (2009) Generation of transgenic non-human primates with germline transmission. Nature 459(7246):523
Schachtschneider KM, Schwind RM, Newson J, Kinachtchouk N, Rizko M, Mendoza-Elias N et al (2017) The oncopig cancer model: an innovative large animal translational oncology platform. Front Oncol 7:190
Schiffman JD, Breen M (2015) Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc B Biol Sci 370(1673):20140231
Segaoula Z, Primot A, Lepretre F, Hedan B, Bouchaert E, Minier K et al (2018) Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology. BMC Cancer 18(1):1219
Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56–61
Staquet M, Byar D, Green S, Rozencweig M (1983) Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 67(9):753–765
Storrs EE, Walsh G, Burchfield H, Binford C (1974) Leprosy in the armadillo: new model for biomedical research. Science 183(4127):851–852
Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11(3):971–981
Sultan F, Ganaie BA (2018) Comparative oncology: integrating human and veterinary medicine. Open Vet J 8(1):25–34
Sun H, Wang H, Taylor R, Risbridger G (2010) Establishment of a xenograft model of human prostate cancer in mouse. Zhonghua Yi Xue Za Zhi 90(30):2136–2139
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9(6):338
Tsutsui H (1918) Über das künstlich erzeugte Cancroid bei der Maus. Gann 12(2):17
Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8(3):346–355
Vollmer G (2003) Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer 10(1):23–42
Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9(11):4227–4239
Weisburger EK, Weisburger JH (1958) Chemistry, carcinogenicity, and metabolism of 2-fluorenamine and related compounds. Adv Cancer Res 5:331–431
Williams SA, Anderson WC, Santaguida MT, Dylla SJ (2013) Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Investig 93(9):970
Winograd B, Boven E, Lobbezoo M, Pinedo H (1987) Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo (Athens, Greece) 1(1):1–13
Withrow SJ, Page R, Vail DM (2013) Withrow and MacEwen’s small animal clinical oncology. Elsevier Health Sciences, St. Louis
Wolf E, Schernthaner W, Zakhartchenko V, Prelle K, Stojkovic M, Brem G (2000) Transgenic technology in farm animals-progress and perspectives. Exp Physiol 85(6):615–625
Wongsrikeao P, Saenz D, Rinkoski T, Otoi T, Poeschla E (2011) Antiviral restriction factor transgenesis in the domestic cat. Nat Methods 8(10):853
Wu X, Gong S, Roy-Burman P, Lee P, Culig Z (2013) Current mouse and cell models in prostate cancer research. Endocr Relat Cancer 20(4):R155–RR70
Yamagiwa K, Ichikawa K (1918) Experimental study of the pathogenesis of carcinoma. J Cancer Res 3(1):1–29
Zhuo Y, Wu Y, Guo A, Chen S, Su J (2010) Establishment and its biological characteristics of patient-derived lung cancer xenograft models. Zhongguo fei ai za zhi 13(6):568–574
Zvibel I, Smets F, Soriano H (2002) Anoikis: roadblock to cell transplantation? Cell Transplant 11(7):621–630
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dhumal, A., Bendale, K., Chaudhari, P. (2019). Preclinical Animal Models for Cancer Research and Drug Discovery. In: Bose, K., Chaudhari, P. (eds) Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. Springer, Singapore. https://doi.org/10.1007/978-981-32-9816-3_9
Download citation
DOI: https://doi.org/10.1007/978-981-32-9816-3_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9815-6
Online ISBN: 978-981-32-9816-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)